A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS,AND EFFICACY OF MOSUNETUZUMAB OR GLOFITAMAB IN COMBINATION WITH CC-220 AND CC-99282 IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA
Primary Objective
To evaluate the safety and select the RP2D of CELMoDs (CC-220 and CC-99282) in combination with mosunetuzumab SC in Cohort A1, Cohort A2, Cohort B1,and Cohort B. To evaluate the safety and select the RP2D of CELMoDs (CC-220 and CC-99282) in combination with glofitamab IV in Cohort C1, Cohort C2, Cohort D1, and Cohort D2
![](https://researchstudies.cuanschutz.edu/Content/images/study-category-images/cancer.jpg)
Details
Age
Adult
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
![Photograph of MANALI KAMDAR](https://som.ucdenver.edu/FIMS/Content/faculty/22517/CU-Doctors-22517.jpg)
MANALI KAMDAR
Study ID
Protocol Number: 22-0939
More information available at ClinicalTrials.gov: NCT05169515
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers